Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study
2012 ◽
Vol 134
(1)
◽
pp. 283-289
◽
Keyword(s):
2011 ◽
Keyword(s):
Keyword(s):
2011 ◽
Vol 17
(2)
◽
pp. 96-104
◽
Keyword(s):
Keyword(s):
2011 ◽
2019 ◽
Keyword(s):
Keyword(s):